ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY

Contributed by: PR Newswire

Tags

Isomorphic-Labs

More Like This

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH NOVARTIS

Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target

Debiopharm & WhiteLab Genomics Announce a Strategic Partnership to Advance Drug Target and Design in Oncology

PR Newswire associated0

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing

TNL’s AI Digital Cells Lab platform and Debiopharm’s deep pharmaceutical expertise may bring cancer drugs into new frontiers of innovation (Graphic: Business Wire)

Debiopharm and ThinkingNodeLife.ai Forge a Strategic Partnership to Propel Cancer Drug Development with AI Digital Cell Clones

MiLaboratories co-founders: Dmitry Chudakov, Stan Poslavsky, Dmitry Bolotin, Alexey Nechaev (Photo: Business Wire)

MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research

PR Newswire associated0

Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted Immunomodulators